{"filing":{"accession_number":"0001213900-26-079444","cik":"0001912966","ticker":"RGNT","company_name":"REGENTIS BIOMATERIALS LTD.","form":"6-K","filing_date":"2026-07-20","report_date":null,"primary_document":"ea0298523-6k_regentis.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1912966/000121390026079444/ea0298523-6k_regentis.htm"},"events":[{"id":18683,"run_id":16801,"accession_number":"0001213900-26-079444","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The exhibit announces a Japanese patent allowance for Regentis' proprietary manufacturing technology underlying GelrinC, its lead regenerative medicine product. This is a material operational/strategic event: the patent strengthens IP protection in a major market (Japan's ~$289M cartilage repair market by 2030), supports competitive advantage through manufacturing efficiency gains (5x yield increase), and facilitates future commercialization in a key international market. While not a discrete transaction (M\u0026A), financial event (debt/equity), or personnel change, the patent allowance is a significant milestone that would affect a reasonable investor's assessment of the company's long-term value and market position.","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-07-20","form":"6-K","submitted_at":null,"items":[{"id":17563,"accession_number":"0001213900-26-079444","item_number":"EX-99.1","item_title":"ea029852301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces a Japanese patent allowance for Regentis' proprietary manufacturing technology underlying GelrinC, its lead regenerative medicine product. This is a material operational/strategic event: the patent strengthens IP protection in a major market (Japan's ~$289M cartilage repair market by 2030), supports competitive advantage through manufacturing efficiency gains (5x yield increase), and facilitates future commercialization in a key international market. While not a discrete transaction (M\u0026A), financial event (debt/equity), or personnel change, the patent allowance is a significant milestone that would affect a reasonable investor's assessment of the company's long-term value and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:12:39.020265+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17563,"accession_number":"0001213900-26-079444","item_number":"EX-99.1","item_title":"ea029852301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces a Japanese patent allowance for Regentis' proprietary manufacturing technology underlying GelrinC, its lead regenerative medicine product. This is a material operational/strategic event: the patent strengthens IP protection in a major market (Japan's ~$289M cartilage repair market by 2030), supports competitive advantage through manufacturing efficiency gains (5x yield increase), and facilitates future commercialization in a key international market. While not a discrete transaction (M\u0026A), financial event (debt/equity), or personnel change, the patent allowance is a significant milestone that would affect a reasonable investor's assessment of the company's long-term value and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:12:39.020265+00:00","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-07-20"}]}